SEC Form 4 · accession 0001144204-15-003557
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gad Berdugo
Officer — EVP & CFO
Period of report
Jan 22, 2015
Accepted (ET)
Jan 23, 2015 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $1.92 | Jan 22, 2015 | A | 370,000 | A | — | Jan 22, 2025 | Common Stock | 370,000 | 370,000 | D |
Explanation of responses
- F1The stock options shall vest over a three-year period, with 1/3 of the stock options granted vesting annually commencing on January 22, 2016.
- F2These securities were issued pursuant to an employment agreement, dated January 21, 2015, entered into between the Issuer and the Reporting Person in connection with the appointment of the Reporting Person as Executive Vice President and Chief Financial Officer of the Issuer, effective January 22, 2015.